| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 165.44 |
| Total Income | 167.41 |
| Expenditure | 160.14 |
| PBT | 7.26 |
| Net Profit | 6.00 |
| OPM | 9.24% |
| NPM | 3.59% |
| EPS | 12.71 |
Fredun Pharmaceuticals Reports Robust Q4 & FY25 Performance with 41.8% YoY Total Income Growth and 33.2% YoY PAT Growth
31 May 2025 · 31 May 2025, 05:32 am
Summary
Fredun Pharmaceuticals Limited, a leading provider of pharmaceuticals and innovative healthcare solutions, announced their financial results for the quarter and year ended March 31, 2025. The company reported a 41.8% YoY growth in total income and a 33.2% YoY growth in PAT.
Key Highlights
- 1
Total Income: Rs. 456.3 Cr in FY25 | Rs. 167.4 in Q4FY25
- 2
EBITDA: Rs. 55.1 Cr in FY25 | Rs. 17.4 in Q4FY25
- 3
EBITDA Margin: 12.1% in FY25 | 10.4% in Q4FY25
- 4
PAT: Rs. 20.8 Cr in FY25 | Rs. 7.1 in Q4FY25
- 5
Foray into Large Animal Veterinary Products with FREOSSI Large Animals brand
- 6
International Expansion of Freossi Petcare Division in Sri Lanka
- 7
Secured a significant tender from the Tamil Nadu Medical Services Corporation for generic medicines
Management Comments
Mr. Fredun Medhora
Managing Director
This year has been a transformative period for Fredun Pharmaceuticals, characterized by expansion and strategic initiatives. Our commitment to enhancing our product offerings and establishing a robust Non-Pharma business is paving the way for increased profitability and strong growth. As we navigate through this dynamic landscape, we remain focused on delivering high-quality healthcare solutions that cater to the diverse needs of our customers.
Informational and educational content only. Not investment advice.